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Blood-Based Biomarkers
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Abstract Introduction: For early detection of Alzheimer’s disease (AD), the field needs biomarkers that can
be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also
known as clusterin) has long been associated with AD pathogenesis through various pathways.
The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD.
Methods: Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present
study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels
were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele sta-
tus, mini-mental state examination score, plasma amyloid beta (Ab), neocortical Ab burden (asmeasured
by Pittsburgh compound B-positron emission tomography), and total adjusted hippocampus volume.
Results: ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as
compared with healthy controls (HC; P, .0001). ApoJ significantly correlated with both “standard-
ized uptake value ratio” (SUVR) and hippocampus volume and weakly correlated with the plasma
Ab1–42/Ab1–40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% ac-
curacy for AD and greater than 75% accuracy for MCI at both baseline and 18-month time points.
Discussion: Mean apoJ levels were significantly higher in bothMCI and AD groups. ApoJ was able to
differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indi-
cating that itmay be included in a biomarker panel to identifyADbefore the onset of clinical symptoms.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Apolipoprotein J (ApoJ), also popularly known as clus-
terin, is an extracellular chaperone protein that is part of the
defense machinery acting against extracellular protein
1www.aibl.csiro.au
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misfolding [1,2]. ApoJ has been previously associated with
Alzheimer’s disease (AD) pathogenesis [3]. Studies have
shown that apoJ inhibits formation of amyloid beta (Ab) de-
posits and thereby its toxicity by interacting with prefibrillar
species and inhibiting fibril formation [4,5]. Various
genome-wide association studies have also linked apoJ with
AD by identifying the clusterin gene (CLU) as one of the
strong genetic loci for AD [6–8]. This has led many groups
to investigate apoJ as a potential peripheral diagnostic
marker for AD [7,9,10]. Plasma apoJ levels have previously
associated with entorhinal cortex atrophy and disease
severity; however, this study found no differences in actual
plasma levels between healthy and AD participants [10]. In
another study, plasma apoJ levels were found to be higher in
AD participants compared with healthy controls (HC) and
correlated with disease severity [11]. IJsselstijn et al. [12]
showed that serum apoJ levels were not increased in presymp-
tomatic AD compared with controls in a set of 43 participants
who were diagnosed with AD during a 10-year follow-up
study. Another study concluded apoJ to be not good enough
as a diagnostic biomarker for AD where they showed similar
plasma apoJ levels in controls, AD, and patients with other de-
mentias [13]. This body of literature clearly indicates that
there is a general lack of consensus as to the efficacy of
apoJ as a blood biomarker for AD. The aim of this present
study was to address this lack of agreement by assaying the
levels of apoJ in plasma samples obtained at baseline and
follow-up time points from the highly characterized Austra-
lian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
cohort. AIBL consists of volunteers fromdifferent clinical cat-
egories namely HCs, mild cognitively impaired (MCI), and
patients with AD.
2. Methods
2.1. Population sample
2.1.1. The AIBL cohort
The AIBL study is a prospective, longitudinal study,
following participants at 18-month intervals. The cohort
recruitment process including the neuropsychological, life-
style, and mood assessments have been previously described
in detail [14]. In brief, the AIBL study recruited a total of
1166 participants aged .60 years at baseline, of whom 54
were excluded because of comorbid disorders or consent
withdrawal. Using the National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) international criteria for AD diagnosis
[15], a clinical review panel determined disease classifica-
tions at each assessment time point to ensure accurate and
consistent diagnoses among the participants. According to
these diagnostic criteria, participants were classified into
one of three groups; AD, MCI, or HC. At baseline, there
were a total of 768 HC, 133 MCI, and 211 AD subjects.
This study reports on 833 individuals at baseline and 824
individuals at 18 months who completed the full study
assessment and corresponding blood sample collection at
both baseline and 18-month follow-up. A subgroup of these
participants also underwent brain imaging with carbon-11-
labeled Pittsburgh compound B-positron emission tomogra-
phy (11C-PiB-PET) and magnetic resonance imaging (MRI)
as listed in Table 1.
The institutional ethics committees of Austin Health, St.
Vincent’s Health, Hollywood Private Hospital, and Edith
Cowan University granted ethics approval for the AIBL
study. All volunteers gave written informed consent before
participating in the study.
2.2. Sample collection and apolipoprotein E (APOE)
genotyping
Plasma was isolated from whole blood and collected in
standardEDTA tubeswithprostaglandinE1 (33.3 ng/mL, Sap-
phire Biosciences, NSW, Australia) added. On completion of
blood fractionation, samples were aliquoted and immediately
stored in liquid nitrogen until required for analysis. DNA
was isolated from whole blood using a QIAamp DNA Blood
Midi Kit (Qiagen, VIC, Australia) according to the manufac-
turer’s protocol, and APOE genotype was determined through
TaqMan genotyping assays (Life Technologies, Mulgrave,
VIC, Australia) for rs7412 (Assay ID: C____904973_10)
and rs429358 (Assay ID:C___3084793_20) [16]. ForTaqMan
assays, polymerase chain reactions and real-time fluorescence
measurements were carried out on a QuantStudio real-time
PCR system (Applied Biosystems, VIC, Australia) using the
TaqMan GTXpress Master Mix (Life Technologies) meth-
odology as per manufacturer’s instructions.
2.3. Plasma apoJ assay
Plasma apoJ levels were assayed using a commercial
quantitative sandwich enzyme-linked immunosorbent assay
(ELISA; R&D Systems, USA). The plasma samples were
thawed on ice, centrifuged for 10 minutes at 12,000! g,
and diluted 4000-fold using the supplied Calibrator Diluent
RD5T. All the reagents were brought to room temperature
before use. The kit uses a monoclonal antibody specific for
apoJ that has been precoated onto a microplate. Briefly,
100 mL of Assay Diluent RD1-19 was added to each well,
followed by 50 mL of standard or sample per well. The plate
is then kept at room temperature on a horizontal orbital mi-
croplate shaker for incubation for 2 hours. The plate is then
washed to remove any unbound substances; an enzyme-
linked monoclonal antibody specific for apoJ is added to
the wells. After a wash to remove any unbound antibody-
enzyme reagent, a substrate solution is added to the wells
and color develops in proportion to the amount of apoJ
bound in the initial step. The color development is stopped,
and the intensity of the color was then measured using a
BMG microplate reader at 450 nm.
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2.4. Evaluation of neocortical Ab and hippocampus
volume via PiB-PET and MRI
A subset of the AIBL cohort (n 5 287) underwent
11C-PiB-PET imaging at baseline to measure cerebral
amyloid load, as previously described [17]. Imaging was
carried out using a Phillips Allegro PET camera.
The sorted sinograms were reconstructed using a three-
dimensional row-action maximization likelihood algorithm
(RAMLA) algorithm. Ab burden was calculated as the
average of the mean of frontal, superior parietal, lateral tem-
poral, lateral occipital, and anterior and posterior cingulate
region of interest (ROI) activity per voxel divided by the
cerebellar gray matter voxel activity and termed the stan-
dardized uptake value ratio (SUVR). The cerebellar cortex
was used as a reference region because of no PiB binding
shown in either controls or AD. Of the total 833 participants
reported here, 207 individuals underwent 11C-PiB-PET im-
aging at baseline and 189 underwent at 18-month follow-
up. In addition, 3D T1 MPRAGE (magnetization-prepared
rapid acquisition gradient echo) and a T2 TurboSpin echo
and FLAIR (fluid-attenuated inversion recovery) sequence
MRI were acquired for screening and co-registration with
the PET images. MRI measurements were performed on
Siemens Avanto 1.5 T scanner. Co-registration of the PET
images with each individual’s MRI was performed with
SPM2 (statistical parametric mapping). For registration pur-
poses, the initial frames of the dynamic PET studies were
summed. Mean radioactivity values were obtained from
ROIs for cortical, subcortical, and cerebellar regions. Hippo-
campal volume was calculated from T1 MPRAGE images
and was normalized by dividing with the total intracranial
volume consisting of the sum of the cerebrospinal fluid,
gray matter, and white matter volumes. Of the total 833 par-
ticipants reported here, 189 individuals underwent MRI at
baseline, whereas 173 individuals were scanned at the 18-
month follow-up.
2.5. Statistical methodology
Descriptive statistics including means, standard devia-
tions (SDs), and frequencies were calculated across clinical
classifications. Comparisons in frequencies of gender and
APOE ε4 allele comparisons were calculated using c2 test
and Fisher’s exact where necessary. P values, calculated
from the analysis of mean apoJ levels between clinical
classifications adjusted for age, gender, and APOE ε4 allele
status, were derived using polynomial ordered logistic
regression and generalized linear modeling (GLM) for
three-group and two-group comparisons, respectively.
Linear mixed models (LMM) were used to define P values
for the comparison of mean apoJ levels between HC and
MCI, and HC and AD participants over time, adjusted for
age, gender, and APOE ε4 allele status. Spearman’s correla-
tion coefficients were calculated to describe the relationship
between apoJ and plasma Ab, SUVR, and hippocampal vol-
ume. Testing across the lower range of SUVR values, four
different threshold values (1.3, 1.4, 1.5, and 1.8) for SUVR
were tested to find the most appropriate criterion for
biomarker evaluation before the 1.8 cutoff being chosen.
GLM combined with receiver operating characteristic
(ROC) analyses were combined to perform 100-fold cross-
validated disease predictions. The R statistical software
environment, version 2.15, was used for all statistical ana-
lyses (Team, R Development Core. 2009. R: A Language
and Environment for Statistical Computing Manual).
3. Results
3.1. Population demographics
Baseline and 18-month follow-up demographic data,
APOE genotype, and mini-mental state examination
(MMSE) for the AIBL cohort are presented in Table 1.
SUV ratios for PiB-PET and hippocampal volume from
Table 1
Demographics of the cohort analyzed in this study, means and standard deviation for age, and PiB-PET SUVR and interquartile range for MMSE
Categories
HC MCI AD P value
Baseline 18 mo Baseline 18 mo Baseline 18 mo Baseline 18 mo
Count (n) 590 576 93 70 150 178
Age, mean (6SD) 70.72 (6.9) 72.07 (6.73) 75.84 (7.31) 76.67 (7.44) 77.89 (7.66) 79.31 (7.65) ,.0001 ,.0001
Gender (n, %F) 335 (57) 331 (58) 52 (56) 38 (54) 88 (59) 105 (59) .890 .800
APOE ε4 positive, % 189 (32) 182 (32) 49 (53) 30 (43) 99 (66) 121 (68) ,.0001 ,.0001
MMSE (IQR) 29 (2) 29 (2) 27 (3) 27 (3) 20 (5) 18 (9) ,.0001 ,.0001
PiB-PET subgroup (n) 144 140 42 27 21 22
PiB SUVR 1.41 (0.4) 1.39 (0.38) 1.91 (0.58) 1.84 (0.64) 2.34 (0.46) 2.35 (0.44) ,.0001 ,.0001
MRI subgroup (n) 137 132 36 23 16 18
Hippocampus volume (mean) 0.0041 0.0041 0.0038 0.0038 0.0036 0.0034 ,.0001 ,.0001
Hippocampus volume (SD) 0.0003 0.0003 0.0005 0.0005 0.0004 0.0004 ,.0001 ,.0001
Abbreviations: SD, standard deviation; PiB-PET, Pittsburgh compound B-positron emission tomography; SUVR, standardized uptake value ratio; MMSE,
mini-mental state examination; HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease;APOE ε4, apolipoprotein ε4; IQR, interquartile
range; MRI, magnetic resonance imaging.
NOTE. P values shown are unadjusted.
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MRI for the AIBL imaging subcohort are also presented in
Table 1. ApoJ data were available for 590 HCs, 93 partici-
pants with MCI, and 150 participants with AD at baseline,
and 576 HC, 93 participants with MCI, and 178 participants
with AD at 18 months. Nine participants were withdrawn
from the AIBL study in the 18-month interim period. Age,
APOE ε4 allele status, and MMSE were significantly
different between clinical classifications at both baseline
and 18months (P, .0001; Table 1). There was no difference
in the proportion of females to males at either time point
(P. .05). Total number of participants from the AIBL imag-
ing subcohort was lower compared with that in the total
group; however, we found no significant difference in
mean apoJ levels between those participants included in
the complete cohort as compared with those in the imaging
subcohort (P. .05). SUVR was significantly higher and to-
tal adjusted hippocampus volume was significantly lower in
the MCI and AD groups as compared with those in the HC
group (P , .0001; Table 1).
3.2. Mean apoJ levels are higher in MCI/AD participants
compared with those in HCs
ApoJ levels were consistent between time points (Pear-
son’s correlation coefficient R 5 0.7, P , .0001). Mean
apoJ levels were significantly higher in both MCI and AD
groups as compared with those in the HC group at both
baseline and 18 months (P values for all tests where there
were sufficient numbers to analyze the data were ,.0001,
Tables 2 and 3, Fig. 1A); however, the levels were not
different between MCI and AD groups (P . .05, data not
shown). We conducted stratified analyses for APOE ε4
allele status (Fig. 1B), gender (Fig. 1C), and age group
(Fig. 1D), with significant differences in apoJ identified be-
tween HC and both MCI and AD for most stratification cat-
egories (P values for all tests where there were sufficient
numbers to analyze the data were ,.05). ApoJ levels
were not significantly different between males and females,
APOE ε4 allele carriers and noncarriers, and older and
younger participants across both time points (P . .05,
data not shown). Adjustment for age, gender, and APOE
ε4 allele status did not affect the outcome compared with
unadjusted analyses. Using the longitudinal nature of the
AIBL study, we compared mean apoJ levels between clin-
ical classifications over time (HC vs. MCI and HC vs. AD,
LMM). We found that the difference in apoJ levels between
clinical classifications remained statistically significant
(P, .0001 for both comparisons) and that there was no sig-
nificant change in apoJ levels between baseline and
18 months (P . .05).
3.3. Association between apoJ and hippocampus volume
and SUVR
We conducted Spearman’s correlation analyses between
both adjusted total hippocampus volume and SUVR with
apoJ levels at both baseline and 18 months. ApoJ was nega-
tively correlated with adjusted total hippocampus volume in
the whole group (baseline, R 5 20.257, P 5 .0004;
18 months, R 5 20.178, P 5 .019). Assessing the correla-
tion within clinical classification showed the strongest asso-
ciation was within the AD group but only at the 18-month
time point (R520.445, P5 .066, Table 4). Using the three
clinical classifications together identified a positive correla-
tion between SUVR and apoJ at both baseline and 18months
(baseline R 5 0.242, P 5 .0004; 18 months, R 5 0.277,
P5 .0001; Table 4), whereas assessing the groups individu-
ally did not reveal any significant correlations between apoJ
and SUVR (Table 4).
3.4. APOE ε4 allele–specific apoJ comparisons
Investigation of the imaging subcohort identified a signif-
icant interaction for apoJ levels between APOE ε4 allele sta-
tus and neocortical Ab burden (as measured by 11C-PiB-PET
Table 2
ApoJ means and standard deviations for stratified subgroup analyses
Categories
Mean (SD)
HC mean (SD) MCI mean (SD) AD mean (SD)
Baseline 18 mo Baseline 18 mo Baseline 18 mo
Total 283.76 (38.98) 289.8 (39.63) 327.33 (41.41) 342.58 (40.87) 347.17 (42.09) 349.38 (38.91)
APOE ε4 2ve 283.69 (39.58) 290.9 (39.94) 328.33 (37.61) 344.27 (42.74) 343.03 (43.22) 350.03 (41.36)
APOE ε4 1ve 283.92 (37.78) 287.4 (38.94) 326.44 (44.92) 340.31 (38.83) 349.31 (41.55) 349.07 (37.88)
Female 282.13 (37.72) 290.82 (40.2) 323.96 (43.78) 346.32 (42.91) 347.04 (45.07) 347.16 (39.51)
Male 285.91 (40.55) 288.41 (38.87) 331.6 (38.3) 338.13 (38.49) 347.36 (37.81) 352.56 (38.08)
Age
,65 282.92 (36.65) 290.75 (41.29) 316.3 (51.12) 326.75 (45.23) 351.31 (36.9) 346.7 (39.36)
65–75 283.78 (39.89) 289.08 (38.45) 333.82 (41.66) 343.69 (40.44) 347.94 (45.56) 354.66 (33.77)
75–85 286.22 (40.44) 293.49 (40.89) 323.61 (40.42) 341.09 (42.6) 347.74 (39.83) 352.68 (37.22)
.85 272.24 (31.3) 272.65 (36.66) 329.86 (40.72) 354.86 (36.01) 343.3 (45.61) 343.62 (42.59)
Abbreviations: APoJ, apolipoprotein J; SD, standard deviation; HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE ε4,
apolipoprotein ε4.
NOTE. NA means not enough participants in group to calculate mean and standard deviation.
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1.8/.1.8, HC group only, P 5 .03 [GLM]). When
comparing HC participants without an APOE ε4 allele, those
participants with an SUVR of .1.8 had lower mean apoJ
levels (baseline mean apoJ 264.4 [SD 6 33.3], 18-month
mean apoJ 273.9 [SD 6 34.0]) compared with those with
an SUVR of 1.8 (baseline mean apoJ 279.9 [SD 6 41.2],
18-month mean apoJ 284.8 [SD6 41.3]). Conversely, those
HC participants with an APOE ε4 allele with an SUVR
of .1.8 had much higher mean apoJ levels (baseline mean
apoJ 310.4 [SD 6 45.8], 18-month mean apoJ 301.9
[SD 6 49.6]) compared with those of an SUVR of 1.8
(baseline mean apoJ 285.0 [SD 6 40.4], 18-month mean
apoJ 292.1 [SD 6 37.4]; Fig. 2B). A similar relationship
was shown for the MCI group (Fig. 2C). Using the standard
SUVR threshold of 1.5 and lower (1.3 and 1.4) did not show
the same interactions.
Table 3
P values for the mean difference between HC and MCI and HC and AD groups at both baseline and at 18 mo for each of the stratified categories
Stratification
All groups HC versus MCI HC versus AD
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Baseline 18 mo Baseline 18 mo Baseline 18 mo Baseline 18 mo Baseline 18 mo Baseline 18 mo
Total 1.73E-64 5.80E-67 1.30E-35 1.30E-35 8.38E-22 7.28E-24 7.06E-21 8.97E-23 1.28E-57 2.31E-58 2.11E-48 9.83E-50
APOE ε4 2ve 5.53E-27 6.95E-30 6.74E-19 1.46E-19 3.96E-12 1.15E-14 4.70E-13 1.40E-14 2.56E-21 7.70E-23 1.66E-21 8.91E-23
APOE ε4 1ve 1.43E-32 8.97E-35 1.00E-17 1.65E-17 1.19E-10 6.07E-11 6.81E-08 7.84E-09 2.23E-32 2.41E-33 1.80E-24 2.72E-25
Female 3.39E-38 5.44E-36 1.39E-21 3.94E-20 1.94E-12 1.61E-14 5.40E-12 3.23E-14 6.94E-36 4.30E-31 3.10E-30 1.81E-26
Male 4.63E-27 5.26E-32 1.32E-15 1.18E-17 8.05E-11 6.03E-11 3.47E-10 7.49E-10 1.77E-23 3.65E-29 9.91E-20 6.02E-25
Age
,65 3.37E-08 0.0002 6.06E-06 0.0004 0.0222 1.0000 0.0441 1.0000 1.57E-08 8.50E-05 6.71E-09 0.0001
65–75 1.75E-23 1.75E-26 7.21E-16 1.05E-16 3.13E-11 4.97E-11 5.03E-12 1.33E-11 6.60E-19 9.09E-22 8.20E-18 8.45E-22
75–85 6.53E-21 3.48E-23 1.14E-13 1.52E-15 2.75E-07 6.26E-09 1.11E-05 7.98E-09 2.32E-20 5.44E-22 2.19E-16 7.81E-20
.85 9.53E-07 2.87E-09 0.0001 4.05E-05 0.0005 1.54E-05 1.0000 0.0001 3.20E-07 3.16E-09 1.0000 5.73E-07
Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE ε4, apolipoprotein ε4.
NOTE. A value of 1.000 represents not enough participants in the subgroup for a valid statistical test
Fig. 1. Box and whisker plot of apoJ levels between clinical classification and time point. (A) ApoJ by clinical classification, (B) ApoJ by classification and
apolipoprotein ε4, (C) ApoJ by clinical classification and gender, and (D) ApoJ by clinical classification and age group. Abbreviations: APoJ, apolipoprotein J;
HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE ε4, apolipoprotein ε4.
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3.5. Association between apoJ and plasma Ab
Investigating the relationship between plasma Ab and
apoJ identified weakly negative, but significant, correlation
between the ratio of Ab1–42/Ab1–40 at both baseline and
18-month time points (baseline R 5 20.08, P 5 .004;
18 months, R 5 20.08, P 5 .004). ApoJ was also weakly
correlated with Abn-40 at the 18-month time point
(R 5 20.10, P 5 .0001). Subgroup correlations identified
a significant but weak negative correlation between Ab1–
40 and apoJ for MCI participants at baseline
(R 5 20.232, P 5 .008), but this was not observed at the
18-month time point.
3.6. Disease predictions using clinical classification
Using the GLM and ROC analyses to predict AD using
apoJ, age, gender, and APOE ε4 allele status, we identified
an 8% increase in cross-validated accuracy over age, gender,
and APOE ε4 allele status alone at baseline and a 6% in-
crease in cross-validated accuracy at the 18-month time
point (sensitivity and specificity at baseline, 84% and at
the 18-month time point, 80%). Similar to the AD predic-
tions, using apoJ to predict MCI at baseline was approxi-
mately 7% better than using age, gender, and APOE ε4
allele status alone (sensitivity and specificity, 75%). Howev-
er, the same prediction using the 18-month time point iden-
tified a 13% increase in accuracy over age, gender, and
APOE ε4 allele status alone (sensitivity and specificity,
80%). Predictions for AD did not include data from the
MCI group, and predictions for the MCI group did not
include data from the AD group.
Fig. 2. ApoJ levels between apolipoprotein ε4 allele status. (A) Complete PiB-PET imaging subgroup, (B) HC from the PiB-PET imaging subgroup only, (C)
MCI from the PiB-PET imaging subgroup only, and (D) AD from the PiB-PET imaging subgroup only. Abbreviations: APoJ, apolipoprotein J; APOE ε4, apoli-
poprotein ε4; SUVR, standardized uptake value ratio; AD, Alzheimer’s disease; MCI, mild cognitive impairment; HC, healthy control; PiB-PET, Pittsburgh
compound B-positron emission tomography.
Table 4
Spearman’s correlations R and associate P values for both whole groups and
groups stratified by clinical classification
Clinical
classification Characteristic
Baseline 18 mo
R P value R P value
Whole group Hippocampus 20.257 .0004 20.178 .019
HC Hippocampus 20.081 .347 0.065 .460
MCI Hippocampus 20.141 .410 20.121 .582
AD Hippocampus 20.032 .908 20.445 .066
Whole group SUVR 0.242 .0004 0.277 .0001
HC SUVR 0.027 .749 0.078 .359
MCI SUVR 20.003 .983 0.358 .067
AD SUVR 20.327 .148 20.134 .551
Abbreviations: HC, healthy control; MCI, mild cognitive impairment;
AD, Alzheimer’s disease; hippocampus, total hippocampus volume
adjusted for intracranial volume; SUVR, standardized uptake value ratio.
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4. Discussion
The AIBL study of aging is world leading in terms of the
thorough clinical classification of participants, rigorous
blood sample preparation, and storage. The longitudinal na-
ture and presence of associated clinical data makes AIBL a
very unique cohort to track the biochemical changes of a
protein blood biomarker over a period of time. This cohort
is particularly strengthened by the inclusion of state-of-
the-art brain amyloid imaging through 11C-PiB-PET and
presence of brain MRI data. Using such a well-
characterized and large study, we were able to investigate
(1) the associations of plasma apoJ levels with the presence
and severity of AD and (B) if plasma apoJ might be a suit-
able candidate as an early diagnostic marker for AD.
The present study shows that apoJ levels are significantly
higher in MCI and AD groups compared with those in the
HC group at both baseline and 18-month follow-up. These
findings suggest early involvement of apoJ in the disease
process.
Our results also suggest a relationship between apoJ
levels and brain Ab as determined by SUVR. Plasma
apoJ levels showed a positive correlation with SUVR
derived from PiB-PET suggesting higher apoJ levels with
increasing severity of the disease as indicated by increased
deposition of Ab in the brain. The carriage of APOE ε4
allele had a significant impact on the association between
apoJ and brain Ab levels. In APOE ε4 allele carriers, partic-
ipants with SUVR above the cutoff of 1.8 had higher
plasma apoJ levels compared with the ones who had
SUVR below the 1.8 cutoff. However, this relationship
was reversed in APOE ε4 allele noncarriers, as participants
with SUVR above the cutoff of 1.8 had lower plasma apoJ
levels compared with the ones who had SUVR below the
1.8 cutoff. This relationship between plasma apoJ levels
and SUVR, however, was only seen in HC and MCI clinical
categories. We have previously shown that levels of another
potential biomarker namely apolipoprotein E (apoE) go
down in plasma, APOE ε4 carriers, and during AD patho-
genesis [18]. Our observation of positive correlation of
apoJ levels with SUVR scores specifically in APOE ε4 car-
riers could be as a result of a compensatory mechanism ex-
erted by the chaperonic activity of apoJ in plasma.
Differences such as these provide us with an indication
that plasma apoJ levels may be used in conjunction with
APOE ε4 allele carriage information to identify candidates
in need of PET imaging for assessment of neocortical am-
yloid burden. This combined information may also be used
to distinguish those HC and MCI participants who are at an
increased risk of progressing further into the disease.
Hence, plasma apoJ levels may be used as the first step in
a multistep neurodiagnostic process with all screen posi-
tives referred for neuroimaging for confirmatory diagnostic
processes. This is exactly how cardiology, oncology, and
infection disease screens and diagnostic and treatment ap-
proaches work in the existing medical infrastructure.
Our finding of a positive correlation of apoJ in HC and
MCI with brain Ab load demonstrates that apoJ is raised
very early in AD pathogenesis and is not just an end-stage
response to this etiopathologic event. Previous studies
have shown that apoJ is a chaperonic protein and helps in
the regulation of Ab by a clearance mechanism where bind-
ing of Ab to apoJ leads to its efflux from the brain [1,19]. Our
finding of inverse relationship between plasma Ab and apoJ
possibly demonstrates the chaperonic effect of apoJ in the
periphery. Hence, it could be speculated that apoJ has a
protective action and not only increases as a result of
drastic events leading to AD.
A similar observation between plasma apoJ levels and dis-
ease severity was made with hippocampus volume derived
from brain MRI where plasma apoJ levels correlated nega-
tively with the hippocampal volume, thus indicating higher
apoJ levels with increased hippocampal atrophy. ApoJ has
earlier been shown to be associated with atrophy of the hip-
pocampus, clinical progression, and disease severity [10].
Hippocampal atrophy is known to happen in the early stages
of the disease, during the conversion from MCI to AD, and
even considered as a marker in the late stages of AD [20,21].
These findings were consistent with some of the earlier
studies [10,11,22]. Thambisetty et al. [9], 2012, showed a cor-
relation of plasma apoJ concentration with the longitudinal at-
rophy changes in several regions of the brain in the MCI
group. Another study also showed apoJ levels increased in
post mortem brain tissue in specific regions such as hippocam-
pus and frontal cortex [23]. Thambisetty et al. [10], 2010,
showed increased apoJ messenger RNA in the blood of AD
patients, but therewas no change in gene or protein expression
of apoJ due to variation in the gene single nucleotide polymor-
phisms (SNPs). Mullan et al. [22] showed that plasma apoJ
levels were not only higher in MCI and AD compared with
controls but MCI stage subjects had even higher levels
compared with AD indicating that increase in plasma apoJ
levels may occur as a response to the disease process. Differ-
ences in assaying techniques used (mass spectrometry based
vs. ELISA) and varying blood collection protocols (fasting
vs. nonfasting) may have contributed to the contradictory re-
sults obtained in some of the earlier studies [12,13].
Although the present study has found strong differences in
plasma apoJ between HC and MCI/AD groups, the smaller
imaging subgroup correlation analyses did not demonstrate
the same strength and magnitude. Although some correla-
tions were statistically significant, the magnitude was quite
low, indicating potential relationships hidden behind consid-
erable variance and small sample size. Another limitation of
this study is the use of differential threshold levels for SUVR.
The relationship identified with the APOE ε4 carrier status
was only present in the higher threshold, as compared with
the lower and more commonly used thresholds. This may
suggest that the interaction with theAPOE genotype only oc-
curs at a late stage during brain Ab deposition.
Overall, our findings reinforce the role and implications
of amyloid chaperonic proteins in AD pathogenesis
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suggesting that further examination of this biochemical
pathway may be useful to identify peripheral markers of AD.
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RESEARCH IN CONTEXT
1. Systematic review: Apolipoprotein J (ApoJ; clus-
terin) has attracted a great deal of attention in recent
times in regard to early diagnosis and monitoring of
Alzheimer’s disease (AD); however, its value as a
blood biomarker for AD has not been established yet.
2. Interpretation: We have used plasma samples from
the Australian Imaging, Biomarkers and Lifestyle
(AIBL) study of aging cohort to specifically answer
the question if plasma apoJ can be used for diagnostic
accuracy and whether it has any association with
brain amyloid beta (Ab) accumulation. Our results
show that apoJ levels were higher in mild cognitive
impairment (MCI) and AD compared with controls
and it also correlated positively with neocortical Ab.
3. Future directions: We still need to answer how
plasma apoJ levels change specifically in the “MCI
progressors” by analyzing longitudinal samples
from further time points of collection. This work is
currently underway in our laboratory as AIBL is a
longitudinal study.
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